[Edaily Reporter Kwon Oh Seok ] NGeneBio Co., Ltd.(354200)’s stock price has surged for two consecutive trading days. It appears that buying interest has been pouring in day after day following news that the company plans to expand the supply of its blood cancer diagnostic panel.

According to MP Doctor on the 22nd, as of 9:23 a.m., NGeneBio Co., Ltd.’s stock is trading at 2,085 won, up 14.25% from the previous trading day.
The previous day, the company announced, “We have begun supplying our ‘HEMEaccuTest’ precision diagnostic panel for blood cancers to Seoul National University Bundang Hospital.” As a result, the stock price rose 29.99% that day, trading at the daily upper limit of 1,825 won.
The company explained, “This supply demonstrates that NGeneBio Co., Ltd.’s precision diagnostic business for blood cancers is expanding its clinical application scope, centered on major tertiary general hospitals in Korea.” NGeneBio Co., Ltd. plans to continue its growth momentum by aggressively expanding into domestic and international markets based on its full-cycle panel portfolio, which covers everything from the diagnosis of blood cancers to recurrence monitoring.
NGeneBio Co., Ltd. currently supplies PowerAcuteTest to approximately 20 major tertiary general hospitals in Korea, including Seoul St. Mary’s Hospital and the main campus of Seoul National University Hospital, and this supply to Seoul National University Bundang Hospital further strengthens its domestic clinical references. Overseas, the company is expanding its supply network to countries such as Singapore, Vietnam, Colombia, Germany, and Romania to reinforce its global presence.
This is also translating into strong financial results. NGeneBio Co., Ltd.’s blood cancer panel business has maintained an average annual growth rate of 36% over the past five years. In the first quarter of this year, revenue grew sharply, rising 38% domestically and 102% internationally compared to the same period last year. In particular, the pace of overseas revenue growth is accelerating, and the blood cancer panel business is establishing itself as one of NGeneBio Co., Ltd.’s core growth drivers.